Conversely, treatment with nicotinamide (NAM), a Pan-Sirtuin inhibitor (class III HDAC), did not affect PD-L1 expression in pancreatic cancer cells (Supplementary Fig. S2B), suggesting that only classical HDACs may affect the expression of PD-L1. Here, HDAC9 is linked to familial pancreatic carcinoma.